Josh Baltzell

Josh has spent over 25 years in the healthcare industry working across a broad range of responsibilities and companies ranging from early stage product development and innovation all the way up to public offerings and mergers and acquisitions for mature companies.

Josh currently serves as a Venture Partner at SightLine partners where he focuses on sourcing and managing investments in the health care industry.  Prior to SightLine, Josh was a Managing Director at Split Rock Partners. A lead investor and board member in companies with an aggregate, realized value of over $2 billion, some of his notable past successes as a venture investor include Ardian – acquired by Medtronic for ~$800M, Entellus Medical – acquired by Stryker for ~$700M, RF Surgical – acquired by Medtronic for $235M and SkinMedica – acquired by Allergan for $350M.

In addition to Aegea, Josh currently serves as a board director at  Colorescience, Koya Medical,  Magnolia Medical, and ViewPoint Medical and also serves as an advisor to TMRW.

Josh earned Bachelor degrees in Economics and Philosophy from St. Olaf College and an M.B.A. from The Carlson School at the University of Minnesota.